Scientific Advisory Board
Professor Lynn W. Enquist, PhD
Emeritus Professor in Molecular Biology at Princeton University.
He received his BS degree in Bacteriology at South Dakota State University in 1967. He received his Ph.D. in Microbiology from Medical College of Virginia, Virginia Commonwealth University in 1971 with S. Gaylen Bradley studying streptomyces biology.
He did postdoctoral training at the Roche Institute of Molecular Biology from 1971 to 1973 studying bacteriophage lambda replication and recombination with Ann Skalka. He served in the US Public Health Service from 1973-1981. He was a senior staff fellow at the National Institutes of Health in the laboratory of Dr. Philip Leder working with Robert Weisberg from 1974-1977 studying bacteriophage lambda site-specific recombination and development of recombinant DNA technology. He held a tenured staff position in the National Cancer Institute from 1977 to 1981 where he continued the development of recombinant DNA technology and also began his work on neurotropic herpes viruses. George VandeWoude was his lab chief. In 1981 he left the National Cancer Institute to be Executive Scientist at Molecular Genetics Incorporated in Minnetonka, Minnesota where he worked on recombinant DNA based viral vaccines.
In 1984, he joined DuPont as a Research Leader where he ran a laboratory studying neurotropic viruses.
In 1990, he joined DuPont Merck Pharmaceutical Company where he was a Senior Research Fellow working on developing neurotropic viruses as tools for gene therapy and studying the mammalian nervous system. In 1993, he accepted the position of tenured full professor of Molecular Biology at Princeton University. He was chair of the department of Molecular Biology from 2004 to 2013.
His research interests are in the field of neurovirology, specifically on the mechanisms of herpesvirus spread and pathogenesis in the mammalian nervous system. His laboratory focuses on understanding the molecular mechanisms by which neuroinvasive alpha-herpesviruses invade and spread in the mammalian nervous system and how the nervous system responds to infection. His laboratory develops and uses imaging technology to define the molecular mechanisms of neuronal spread and subsequent pathogenesis. His work has also lead to the development of these viruses as tools to trace neuronal circuitry in living animals. He has published over 300 peer-reviewed papers, reviews, books and has 4 patents.
He is a Fellow of the American Academy of Microbiology and the American Association for the Advancement of Sciences (AAAS). He was member of the board of directors of the AAAS. He was a member of the National Science Advisory Board for Biosecurity. He was a member of the Scientific Council of the Pasteur Institute from 2007-2013. He was elected to the American Academy of Arts and Sciences. He was past President of the American Society for Virology and editor in chief for the Journal of Virology. He is a past president of the American Society for Microbiology and is the founding editor in chief of the Annual Reviews of Virology.
Professor Samuel Rabkin, PhD
Dr. Rabkin is the Thomas A. Pappas Professor in Neurosciences and Professor of Neurosurgery (Microbiology) at Harvard Medical School, Boston MA, and Virologist in Neurosurgery at Massachusetts General Hospital, Boston, MA.
He obtained his PhD in Microbiology at the University of Chicago in 1984, followed by postdoctoral training in the Department of Biological Chemistry at Harvard Medical School. In 1986, he established his own laboratory as an Assistant Member at Memorial Sloan-Kettering Cancer Center in New York City.
He moved to Georgetown University, Washington DC in 1993 as an Assistant Professor in the department of Neurosurgery and Microbiology & Immunology, and then joined the Harvard Medical School and Massachusetts General Hospital, Boston in 2000 as an Associate Professor in Surgery (Microbiology & Immunobiology). At Massachusetts General Hospital, he was chair of the PhD Steering Committee from 2012-2013 and member of the Subcommittee on Animal Resources since 2010.
His research has been in the fields of gene therapy and oncolytic viruses, focusing on herpes simplex virus (HSV) vectors. This includes defective HSV vectors for gene delivery in the CNS and development of oncolytic HSVs for cancer therapy, including the first oncolytic HSV to enter clinical trial in the US and first demonstration of oncolytic virus induced anti-tumor immunity. He has published over 150 papers in academic journals and is an inventor on sixteen U.S. patents.
Dr. Rabkin served on the Scientific Advisory Board of MediGene Inc, San Diego CA from 2001-2009 and the Scientific Expert Panel for Replimune Inc, Woburn MA from 2018-2019. He has been on the Editorial Board of Molecular Therapy since 2005 and currently is an Associate Editor of the Journal for ImmunoTherapy of Cancer. As a member of the American Society for Gene and Cell Therapy since 1998, he served twice on the Viral Gene Transfer Vectors Committee, and has been on the Organizing Committee for the last ten International Oncolytic Viruses for Cancer Therapeutics meetings.
Professor David Fink, MD
Emeritus Professor of Neurology at the University of Michigan.
During his career Dr. Fink worked on the development of recombinant genomic herpes simplex virus-based vectors for the treatment of neurologic conditions including pain, peripheral neuropathy and spinal cord injury.
He is the co-inventor on 6 issued patents related to that technology, co-founded the gene therapy company Theragen, and spearheaded the first human clinical trials of an HSV-based vector for the treatment of pain.
Dr. Fink received his B.A. (1970) degree from Yale College and his M.D. (1974) degree from Harvard Medical School. He completed an internship and residency in internal medicine at the Massachusetts General Hospital in Boston (1974-76), a postdoctoral fellowship in the Laboratory of Neurochemistry at the National Institutes of Health in Bethesda (1976-79), and a residency in neurology at the University of California, San Francisco (1979-82). Dr. Fink was board certified in internal medicine in 1977 and neurology in 1984.
He joined the University of Michigan faculty as an assistant professor in 1982, and was promoted to associate professor in 1988. He then served as a visiting professor (1994-95) and professor (1995-2004) at the University of Pittsburgh.
He returned to Michigan as the Robert W. Brear Professor and chair of the Department of Neurology in 2004, and served in that role until his retirement in 2019.
His work on the development and use of herpes simplex-based viral vectors for the treatment of diseases of the nervous system was funded by the NIH, the Department of Veterans Affairs, and several private foundations continuously for 35 years. He served on the board of the American Neurological Association, on the board and as president of the Association of University Professors of Neurology, and on the board and as vice chair of the United Council for Neurologic Subspecialties. He was awarded the Paul W. Magnuson Award for Outstanding Achievement in Rehabilitation Research by the Department of Veterans Affairs in 2014.
Professor Joseph C Glorioso, PhD
Former Chair and currently Professor of the Dept of Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
Joseph Glorioso has engaged in fundamental studies of the pathogenesis and immunology of herpes simplex virus (HSV) and is a world-wide leader in the development of HSV gene vectors applied to the treatment of human disease using gene therapy strategies. His work has led to the creation of numerous biotech companies for which he serves as a scientific founder and/or consultant. Company missions include treatment of cancer using oncolytic HSV vectors to the treatment of chronic pain by HSV-mediated gene transfer to peripheral nerves.
He is a founding board member of the American Society for Gene and Cell Therapy and former president of the ASGCT, founding editor of the Nature Journal Gene therapy, former president of the National Association of Microbiology and Immunology Medical School Chairs, Former Chair of the American Association for Cancer Gene Therapy, former member of the NIH RAC Committee for review of gene therapy protocols and a former member of the NIH National Gene Vector Laboratory. He is a recipient of the Gene Therapy Pioneer Award from the journal of Human Gene Therapy, Paradigm Builder Lectureship from the International Society of Neurovirology and ASM Award for Applied and Biotechnological Research. He is a Fellow of the American Society for Microbiology and the American Association of the Advancement of Science.